TY - JOUR AU - Kay, George Neal AB - Abstract Aims We report the features of focal ventricular arrhythmias (VAs) arising from the left ventricle (LV) adjacent to the membranous septum. Methods and results We studied eight patients (five men, 65 ± 10 years) with (n = 2) or without structural heart disease (n = 6) who had ventricular tachycardia (n = 4) or premature ventricular contractions (n = 4) originating from the LV septum underneath the aorta. Ventricular arrhythmias exhibited a focal activation pattern, left (n = 4) or right bundle branch block (n = 4), respectively, left superior (n = 4) or inferior axis QRS morphology (n = 4), negative QRS polarity in lead III and early or no precordial transition in all. During all of these VAs, far-field electrograms in the His bundle (HB) region preceded the QRS onset. In all patients, ventricular pre-potentials were recorded during VAs while late potentials were recorded in sinus rhythm at the border of a localized low-voltage area underneath the aorta. Radiofrequency catheter ablation at the presumed sites of origin successfully eliminated VAs in five patients and was abandoned in the remaining three because the HB electrogram was recorded at that site. Conclusion Focal VAs may arise from the LV adjacent to the membranous septum as a part of the LV ostium, and broadens the spectrum of LV ostium VAs. Focal, Ventricular arrhythmia, Left ventricle, Membranous septum, Radiofrequency catheter ablation Introduction The left ventricular outflow tract (LVOT) forms a part of the ostium of the left ventricle (LV) and is known to be one of the major sources of focal ventricular arrhythmias (VAs).1–6 Anatomically, the LVOT consists of the aortic root and the sites below the aortic valve including the aorto-mitral continuity that is located at a lateral site in the LVOT. It has been reported that the aortic root is the most common location of VA origins in the LVOT, followed by the aorto-mitral continuity.4,6 However, VAs arising from other sites in the LVOT have not been described. In this report, we describe a distinct subgroup of focal VAs that arise from the LV septum underneath the aortic valve. Methods The study subjects consisted of eight consecutive patients with symptomatic VAs refractory to at least one antiarrhythmic drug with a focal mechanism that originated from the LV septum underneath the aortic valve. The baseline characteristics of these patients, including their age, gender, LV ejection fraction, presence of structural heart disease, nature of the clinical arrhythmia, and electrocardiogram during the VAs, were recorded. Each patient gave written, informed consent, and all antiarrhythmic drugs were discontinued for at least five half-lives prior to the study. Electrophysiological study For mapping and pacing, standard multielectrode catheters were introduced from the right femoral vein and placed in the coronary sinus, His bundle (HB) region, and right ventricular apex. When few premature ventricular contractions (PVCs) were observed at the beginning of the electrophysiological study, induction of the ventricular tachycardia (VT) or PVCs was attempted by programmed electrical stimulation with one, two, and three extra-stimuli introduced after an 8-beat drive train and burst pacing from the right ventricular apex (to a cycle length as short as 300 ms), with the infusion of isoproterenol if necessary. During procedures in the LV, intravenous heparin was administered to maintain an activated clotting time >250 s. Mapping and ablation Non-fluoroscopic electroanatomic mapping in the ventricles was performed with a 7.5-French quadripolar deflectable 3.5-mm-tip external-irrigated ablation catheter (Navistar ThermoCoolTM, Biosense Webster, Diamond Bar, CA, USA) via the femoral vein and artery or the transseptal approach with a 11.5-French deflectable sheath (Agilis NxT™, St. Jude Medical, AF Division, Minnetonka, MN, USA) in addition to fluoroscopy as previously reported.7,8 Activation mapping was performed in all cases in order to identify the earliest site of ventricular activation during VT or PVCs. Pace mapping was also performed at a pacing cycle length of 500 ms and stimulus amplitude of 1 mA greater than the late diastolic threshold. Ventricular pacing was also performed adjacent to the right ventricular HB region with a stimulus current of 20 mA to capture both the right ventricle (RV) and HB. The score for the pace mapping was determined from the R/S ratio and notch of the R-wave in the 12-lead electrocardiogram as previously reported (perfect pace mapping was equal to 24 points).9 An excellent pace map was defined as a pace map which obtained a score of >20. The site of the ablation catheter was assessed by fluoroscopy and electroanatomic mapping with or without a CARTO-based three-dimensional ultrasound imaging system (CARTO SOUNDTM, Biosense Webster Inc.). Radiofrequency (RF) current was used as the energy source for ablation. Irrigated RF current was delivered in the power-control mode starting at 30 W with an irrigation flow rate of 30 mL/min. The RF power was titrated to as high as 50 W, with the goal being able to achieve a decrease in the impedance of 8–10Ω and with care taken to limit the temperature to <40°C. When an acceleration or reduction in the incidence of VT or PVCs was observed during the first 10 s of the application, the RF delivery was continued for 30–60 s. Otherwise or when junctional rhythm occurred, the RF delivery was terminated, and the catheter was repositioned. The endpoint of the catheter ablation was the elimination and non-inducibility of VT or PVCs during an isoproterenol infusion (2–4µg/min) and burst pacing from the RV (to a cycle length as short as 300 ms). Post-procedure follow-up included clinic visits and telephone calls to all patients and their referring physicians. Results Baseline characteristics The baseline characteristics of the eight patients are shown in Table 1. There were five men and three women between the ages of 48 and 79 years (mean age 65 ± 10 years). Two patients had a history of ischaemic heart disease with severely reduced LV systolic function, but one of them had suffered from the same morphology of VAs before the onset of ischaemic heart disease. One of them had developed complete AV block and had an implantation of a cardiac resynchronization therapy defibrillator. In the other six patients, echocardiography demonstrated normal LV systolic function and no evidence of structural heart disease. The presenting clinical arrhythmia was sustained VT in two patients, non-sustained VT in two, and frequent (>10 000beats/24 h) PVCs without runs of non-sustained VT in four. One patient noted that his symptoms markedly worsened with exertion. None of the eight patients suffered from cardiac arrest or syncope. The duration of symptoms prior to the study ranged between 2 weeks and 12 years. Antiarrhythmic drugs which failed to control the VAs included beta-blockers in six patients, sotalol in two, amiodarone in two, mexiletine in one, and flecainide in one. Table 1 Baseline and arrhythmia characteristics of the study patients Case . 1 . 2 . 3 . 4 . 5 . 6 . 7 . 8 . Baseline  Age, years old 56 48 79 72 74 66 73 57  Sex Male Male Male Male Male Female Female Female  SHD None Inferior MI CHF III ICM CAVB None None None None None  LV ejection fraction (%) 55 35 30 63 60 65 71 56 Arrhythmia  Pattern SVT SVT PVCs NSVT PVCs NSVT PVCs PVCs  Duration of symptoms 5 years 2 weeks 8 years 10 years 12 years 1 year 2 years 8 years  Failed AADs Beta-blocker Sotalol, amiodarone Beta-blocker amiodarone Beta-blocker mexiletine Beta-blocker flecainide Beta-blocker Beta-blocker Sotalol Electrocardiogram  QRS morphology LBBB/LIA LBBB/LSA RBBB/LSA RBBB/LSA RBBB/LSA LBBB/LIA LBBB/LIA RBBB/LIA  QRS duration, ms 147 175 206 172 145 178 168 147  Transition zone V1–V2 V1–V2